Skip to main content

Table 2 Baseline characteristics of patientsa

From: Differences in the quality of oral anticoagulation therapy with vitamin K antagonists in German GP practices – results of the cluster-randomized PICANT trial (Primary Care Management for Optimized Antithrombotic Treatment)

 

Intervention (n = 365)

Control (n = 371)

Total (n = 736)

Sociodemographic characteristics

 

Age, mean (SD), yearsb

74.4 (9.5)

72.8 (9.3)

73.6 (9.4)

Male gender, no. (%)

205 (56.2)

200 (53.9)

405 (55.0)

Educational attainment, no. (%)

 No educational attainment

54 (15.9%)

38 (11.3%)

92 (13.6%)

 Vocational training

2 (0.6%)

0 (0%)

2 (0.3%)

 Vocational on-the-job training

145 (42.8%)

153 (45.4%)

298 (44.1%)

 On-the-job training combined with school-based education

38 (11.2%)

46 (13.6%)

84 (12.4%)

 Education in a technical college

56 (16.5%)

47 (13.9%)

103 (15.2%)

 Polytechnic degree

25 (7.4%)

25 (7.4%)

50 (7.4%)

 University degree

19 (5.6%)

28 (8.3%)

47 (7%)

BMI, mean (SD)

28.8 (5.1)

29.1 (4.8)

28.9 (5.0)

Smoking, no. (%)

 Non-smoker

185 (51.5%)

205 (56%)

390 (53.8%)

 Former smoker

151 (42.1%)

136 (37.2%)

287 (39.6%)

 Occasional smoker

9 (2.5%)

11 (3%)

20 (2.8%)

 Regular smoker

14 (3.9%)

14 (3.8%)

28 (3.9%)

Migration background, no. (%)

27 (7.4)

24 (6.5)

51 (6.9)

Clinical characteristics

Long-term indication for oral anticoagulation therapy, no. (%)c

  Atrial fibrillation/flutter

302 (82.7)

295 (79.5)

597 (81.1)

  Recurrent venous thromboembolism

32 (8.8)

40 (10.8)

72 (9.8)

  Recurrent pulmonary embolism

31 (8.5)

30 (8.1)

61 (8.3)

  Mechanical heart prosthesis

29 (7.9)

28 (7.5)

57 (7.7)

  Intracardiac thrombus

3 (0.8)

4 (1.1)

7 (1.0)

  Other indication

33 (9.0)

34 (9.2)

67 (9.1)

Comorbidities, no. (%)c

 Ischemic heart disease

133 (36.4%)

106 (28.6%)

239 (32.5%)

 Cerebral insult/bleeding

72 (19.7%)

56 (15.1%)

128 (17.4%)

 Congestive heart failure

120 (32.9%)

103 (27.8%)

223 (30.3%)

 Peripheral arterial occlusive disease (PAOD)

39 (10.7%)

26 (7%)

65 (8.8%)

 Arterial hypertension

317 (86.8%)

307 (82.7%)

624 (84.8%)

 Renal insufficiency

62 (17%)

63 (17%)

125 (17%)

 Diabetes mellitus

119 (32.6%)

135 (36.4%)

254 (34.5%)

 Chronic pulmonary diseases

58 (15.9%)

63 (17%)

121 (16.4%)

 Diseases of the esophagus, stomach, duodenum

68 (18.6%)

63 (17%)

131 (17.8%)

 Malignant tumor

18 (4.9%)

23 (6.2%)

41 (5.6%)

CHA2DS2-VASc-Score, no. (%)d

  > 1

292 (97.0)

282 (95.9)

574 (96.5)

  = 1

9 (3.0)

12 (4.1)

21 (3.5)

Antithrombotic medication, no. (%)e

 Phenprocoumon

341 (93.4)

349 (94.1)

690 (93.8)

 Dabigatran

8 (2.2)

4 (1.1)

12 (1.6)

 Rivaroxaban

7 (1.9)

13 (3.5))

20 (2.7)

 Aspirin

4 (1.1)

6 (1.6)

10 (1.4)

 Other

9 (2.5)

3 (0.8)

12 (1.6)

Last INR within therapeutic target range, no. (%)f

240 (69.2)

239 (68.7)

479 (68.9)

INR self-measurement, no. (%)g

39 (11.3)

46 (13.3)

85 (12.3)

Patient compliance, no. (%)h

 Highly compliant

308 (84.4)

266 (72.1)

574 (78.2)

 Moderately compliant

51 (14.0)

86 (23.3)

137 (18.7)

 Not compliant

6 (1.6)

17 (4.6)

23 (3.1)

  1. aThis is a slightly different version of the original table from the main study [24]
  2. bAge was calculated from 15/mm/yyyy since the exact birth date was not documented to ensure data privacy
  3. cPatients may have had more than one indication, and/or more than one comorbidity
  4. dRefers to 595 patients with atrial fibrillation/flutter and available data
  5. eApixaban and Edoxaban had not been approved at the time of the baseline assessment
  6. fOnly considers patients receiving phenprocoumon; target INR range as defined by GP
  7. gDistinction between self-measurement yes and no, dose adjustment not taken into account
  8. hCompliance was assessed for each patient by his GP; data available for 369 patients in control group
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us